The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Glucagon-like peptide-1 inhibits adipose tissue macrophage infiltration and inflammation in an obese mouse model of diabetes
Open accessAbstract
Aims/hypothesis Obesity and insulin resistance are associated with low-grade chronic inflammation. Glucagon-like peptide-1 (GLP-1) is known to reduce insulin resistance. We investigated whether GLP-1 has anti-inflammatory effects on adipose tissue, including adipocytes and adipose tissue macrophages (ATM).Methods We administered a recombinant adenovirus (rAd) producing GLP-1 (rAd-GLP-1) to an ob/ob mouse model of diabetes. We examined insulin sensitivity, body fat mass, the infiltration of ATM and metabolic profiles. We analysed the mRNA expression of inflammatory cytokines, lipogenic genes, and M1 and M2 macrophage-specific genes in adipose tissue by real-time quantitative PCR. We also examined the activation of nuclear factor κB (NF-κB), extracellular signal-regulated kinase 1/2 and Jun N-terminal kinase (JNK) in vivo and in vitro.Results Fat mass, adipocyte size and mRNA expression of lipogenic genes were significantly reduced in adipose tissue of rAd-GLP-1-treated ob/ob mice. Macrophage populations (F4/80(+) and F4/80(+)CD11b(+)CD11c(+) cells), as well as the expression and production of IL-6, TNF-α and monocyte chemoattractant protein-1, were significantly reduced in adipose tissue of rAd-GLP-1-treated ob/ob mice. Expression of M1-specific mRNAs was significantly reduced, but that of M2-specific mRNAs was unchanged in rAd-GLP-1-treated ob/ob mice. NF-κB and JNK activation was significantly reduced in adipose tissue of rAd-GLP-1-treated ob/ob mice. Lipopolysaccharide-induced inflammation was reduced by the GLP-1 receptor agonist, exendin-4, in 3T3-L1 adipocytes and ATM.Conclusions/interpretation We suggest that GLP-1 reduces macrophage infiltration and directly inhibits inflammatory pathways in adipocytes and ATM, possibly contributing to the improvement of insulin sensitivity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the adipose tissue of GLP-1-treated ob/ob mice expressing recombinant adenovirus, for instance, GLP-1RA has been shown to decrease the production of TNF-α, IL-6, and IL-1β, all of which are significant mediators of inflammation.”
From Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications (2024) · cites this paper as [38]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“antiinflammatory benefits have been observed in various preclinical models, such as obesity, atherosclerosis, steatohepatitis, and nephritis, even in the absence of direct immune cell targeting (27–32).”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [27]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“It was reported that GLP-1 shows anti-inflammatory effects on pancreatic islets and adipose tissue, contributing to lowering glucose levels in diabetes [18–20].”
From Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control (2016) · cites this paper as [18]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Administration of a recombinant adenovirus producing GLP-1 (4 × 109 PFU/mouse) to ob/ob mice reduced the macrophage population and production of TNF-α, MCP-1, and IL-6 in adipose tissue via inhibition of nuclear factor-kappa B (NF-κB) activation and phosphorylation of ERK1/2 and c-Jun N-terminal kinases [18].”
From Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control (2016) · cites this paper as [18]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“GLP-1 receptor agonists may potentially reduce inflammation and oxidative stress in adipose tissue by affecting the expression of cytokines, chemokines, and macrophage infiltration, with prolonged GLP-1 action potentially alleviating obesity-related adipose tissue inflammation while enhancing the expression of anti-inflammatory genes [17,18]”
From New Developments in Pharmacological Treatment of Obesity and Type 2 Diabetes—Beyond and within GLP-1 Receptor Agonists (2024) · cites this paper as [17]
Experimental — accuracy not yet measured
The cited source says what the claim attributes to it.
In the citing paper
“Similar antiinflammatory effects of GLP-1 have been reported in human macrophage cell lines (66), and systemic effects of GLP-1 agonists on macrophage infiltration have been previously reported (67).”
From GLP-1 agonists in the treatment of chronic kidney disease in type 2 diabetes and obesity (2025) · cites this paper as [67]
In the citing paper
“Treatment of Huh7 and HepG2 hepatoma cells with exenatide decreased intracellular lipid accumulation [181,182] by enhancing fatty acid oxidation and reducing lipogenesis [160,161,179,183].”
From Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH (2020) · cites this paper as [182]
In the citing paper
“Treatment with GLP-1 RAs is also able to reduce macrophage infiltration of adipose tissue and inhibit inflammatory pathways in adipocytes, concurring to ameliorate insulin sensitivity [138].”
From GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives (2023) · cites this paper as [138]
In the citing paper
“In fact, new research suggests that GLP-1 RAs may reduce the production of pro-inflammatory cytokines and immune cell infiltration to reduce inflammation in many tissues, including AT [73].”
From Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance (2024) · cites this paper as [73]
In the citing paper
“Furthermore, GLP-1 RAs prevent resident macrophages in AT from being activated by nuclear factor-kappa B (NF-κB) [73].”
From Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance (2024) · cites this paper as [73]
In the citing paper
“Studies have shown that GLP-1 and its analogs have anti-inflammatory properties.”
From The Role of Glp-1 Receptor Agonists in Insulin Resistance with Concomitant Obesity Treatment in Polycystic Ovary Syndrome (2022) · cites this paper as [101]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kanda, H. (2006) · Journal of Clinical Investigation · doi:10.1172/jci26498 · Cited by 2,682
Local and systemic insulin resistance resulting from hepatic activation of IKK-β and NF-κB
Cai, D., Yuan, M., Frantz, D. F., Melendez, P. A., Hansen, L., Lee, J., & Shoelson, S. E. (2005) · Nature Medicine · doi:10.1038/nm1166 · Cited by 2,245
The biology of incretin hormones
Drucker, D. J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.004 · Cited by 2,210
Recent advances in the relationship between obesity, inflammation, and insulin resistance.
Bastard, J., Maachi, M., Lagathu, C., Kim, M. J., Caron, M., Vidal, H., Capeau, J., & Fève, B. (2006) · PubMed · Cited by 2,090
NF-κB activation by tumour necrosis factor requires the Akt serine–threonine kinase
Nidai Ozes, O., Mayo, L. D., Gustin, J. A., Pfeffer, S. R., Pfeffer, L. M., & Donner, D. B. (1999) · Nature · doi:10.1038/43466 · Cited by 1,832
IKK-β links inflammation to obesity-induced insulin resistance
Arkan, M. C., Hevener, A. L., Greten, F. R., Maeda, S., Li, Z.-W., Long, J. M., Wynshaw-Boris, A., Poli, G., Olefsky, J., & Karin, M. (2005) · Nature Medicine · doi:10.1038/nm1185 · Cited by 1,773
CCR2 modulates inflammatory and metabolic effects of high-fat feeding
Weisberg, S. P., Hunter, D., Huber, R., Lemieux, J., Slaymaker, S., Vaddi, K., Charo, I., Leibel, R. L., & Jr., A. W. F. (2006) · Journal of Clinical Investigation · doi:10.1172/jci24335 · Cited by 1,497
CCR2 modulates inflammatory and metabolic effects of high-fat feeding
Weisberg, S. P. (2006) · Journal of Clinical Investigation · doi:10.1172/jci24335c1 · Cited by 1,425
Normalization of obesity-associated insulin resistance through immunotherapy
Winer, S., Chan, Y., Paltser, G., Truong, D., Tsui, H., Bahrami, J., Dorfman, R., Wang, Y., Zielenski, J., Mastronardi, F., et al. (2009) · Nature Medicine · doi:10.1038/nm.2001 · Cited by 1,370
Zander, M., Madsbad, S., Madsen, J. L., & Holst, J. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07952-7 · Cited by 1,297
Flagged first, then by citations
Cited by
Sorted by citations
Items 301–319 of 319
Developing treatment strategies to optimize outcomes in patients with psoriatic arthritis
Kharouf, F., Arraf, A., & Chandran, V. (2026) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2026.2667340
Chondroprotective Effect of Semaglutide in Osteoarthritis: Association with Macrophage Polarization
Lei, D., Pang, C., Huang, H., He, Z., & Lu, L. (2026) · Journal of Biosciences and Medicines · doi:10.4236/jbm.2026.145015
Enhanced Bioactivities of Fermented Rehmannia glutinosa via Catalpol-Mediated GLP-1R Signaling
You, E.-J., & Kim, B. R. (2026) · Current Issues in Molecular Biology · doi:10.3390/cimb48060559
Chen, X. T., Tu, B. B., Li, Z., Gao, P., Xu, Y., & Yao, Y. (2026) · Frontiers in Bioscience-Landmark · doi:10.31083/fbl49873
Kotanidou, S., Dampali, R., Devaja, O., Montalto, S. A., Godfrey, M., Papadopoulos, A., Daniilidis, A., Nikolettos, N., & Nikolettos, K. (2026) · Reproductive Medicine · doi:10.3390/reprodmed7030034
Burke, S. J., Galvin, D. M., Nolan, Y. M., Schellekens, H., & Henry, R. J. (2026) · Neurotrauma Reports · doi:10.1177/2689288x261456994
Decoding Immunometabolic Dynamics of Adipose Tissue in Obesity: Evolving Evidence and Way Forward
Kumari, K., Verma, K., Yadav, R., Dwivedi, J., Paliwal, S., & Sharma, S. K. (2026) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.6c00071
Gómez-Maldonado, I., Rodríguez-Arana, A., Tamayo-Pinzón, A., Albornoz-Suárez, J. E., Lopez-Franco, M. J., Mejia-Manrique, J. A., Forero-Caycedo, J. J., Rojas-Rodríguez, L. C., Buitrago-Ricaurte, N., Gaviria-Carrillo, M., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27167108
Xie, Y., Zhang, X., & Chen, B. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1913929
Pavshintsev, V., Erbaeva, A. Z., Vatlin, A., & Mitkin, N. (2026) · Biomedicines · doi:10.3390/biomedicines14091987
Chirapongsathorn, S., & Tacke, F. (2026) · Digestion · doi:10.1159/dig/acmag014
Allaham, L., King, B. J., Ali, F., GUPTA, I., Metuku, R., Nieto, I., Lurie, A., Amer, F. N., Reddy, R., & Alzghoul, B. N. (2026) · Lung · doi:10.1007/s00408-026-00939-2
Álvarez‐Perea, A., Entrala, A., Palomino-Lozano, L., Mazariego, E. R., & Zambrano‐Ibarra, G. (2026) · Clinical & Experimental Allergy · doi:10.1111/cea.70442
Temel, Ş., Ergül, S. Ş., YEŞİLTE, A., Yüksel, R. C., Kaynar, A. S., Sungur, M., & Gündoğan, K. (2026) · Medicine · doi:10.1097/md.0000000000050917
Wang, P., Zhang, J., Zhou, W., Zhang, N., & Chen, Y. (2026) · Journal of Molecular Histology · doi:10.1007/s10735-026-10993-y
Yesho, D. H., Megiso, M. Z., Ugwu, C. J., Neely, A. N., Verinumbe, T., Varadi, G., & Jones, C. (2026) · Supportive Care in Cancer · doi:10.1007/s00520-026-11405-3
Segedi, A., Vesković, D., Nišavić, M., & Levakov, O. (2026) · Medicinski pregled · doi:10.2298/mpns2608189s
Grudniewska, A., Mrozikiewicz‐Rakowska, B., Wiszniewski, K., Filipiak, K. J., & Kuryłowicz, A. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27219692
Metadata
- Authors
- Lee, Y.-S., Park, M.-S., Choung, J.-S., Kim, S.-S., Oh, H.-H., Choi, C.-S., Ha, S.-Y., Kang, Y., Kim, Y., & Jun, H.-S.
- Affiliations
- Gachon University (KR)
- Gachon University Gil Medical Center (KR)
- Ajou University (KR)
- Seoul National University (KR)
- Corresponding author
- Jun, H.-S.
- Venue
- Diabetologia
- Published
- 2012-06-22
- Volume
- 55
- Issue
- 9
- Pages
- 2456-2468
- ISSN
- 0012-186X (ISSN-L)
- 1432-0428
- OpenAlex
- W1993624198
- Cited by
- 319
- References
- 47
- Citations by year
- 2026: 31 · 2025: 34 · 2024: 35 · 2023: 29 · 2022: 25 · 2021: 24 · 2020: 17 · 2019: 26 · 2018: 17 · 2017: 15 · 2016: 17 · 2015: 17 · 2014: 18 · 2013: 12 · 2012: 2
- FWCI
- 11.69
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Diabetologia (publishedVersion)
- PubMed (publishedVersion)
- AJOU Open Repository (Ajou University) (submittedVersion)
- Funders
- National Research Foundation
- National Research Foundation of Korea (A062260)
- Korea Science and Engineering Foundation
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Health Sciences › Medicine › Physiology (medical) › Adipose Tissue and Metabolism
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- glucagon-like peptide-1, adipose tissue macrophages, adipose tissue inflammation, obesity, type 2 diabetes, insulin resistance, ob/ob mice, adipocyte size, lipogenic gene expression, macrophage polarization, NF-κB, JNK, exendin-4, lipopolysaccharide-induced inflammation, adipocyte inflammation, adipose tissue mass
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Adipose Tissue, Animals, Anti-Inflammatory Agents, Gene Expression Regulation, Inflammation, Insulin Resistance, Macrophages, Mice, Obese, Obesity, NF-kappa B, Receptors, Glucagon, Body Fat Distribution, Mice, Glucagon-Like Peptide 1, Real-Time Polymerase Chain Reaction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
